FDA is “redoubling” harmonization efforts
This article was originally published in The Gold Sheet
FDA is working on an exchange of letters with Japan; developing a Memorandum of Understanding with Switzerland; working on a MOU with Australia; and developing an exchange of letters as well as a mutual recognition agreement with the EU, reported Friedman at the June 23 Pharma Conference. In addition, FDA is working on a MOU with Canada, and developing a trilateral cooperation agreement with Canada and Mexico. As a result of these agreements with the EU in particular, Friedman reported that "we could potentially be doing less inspections in the EU in the next couple of years … and more inspections in the emerging economies of China and India." He added that "we are interested in harmonization. We are seeking membership in PIC/S for the reason that PIC/S has more members and more harmonized techniques than ICH
You may also be interested in...
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.